Description
SCK NMA-talk regarding Targeted Radionuclide Therapy| Period | 14 Nov 2023 |
|---|---|
| Held at | Belgian Nuclear Research Center, Belgium |
| Degree of Recognition | National |
Related content
-
Research output
-
Accepted poster session at ImmunoRad 2023: Targeted alpha therapy using Actinium-225 radiolabeled single domain antibodies induces antigen-specific immune responses and instills immunomodulation both systemically and at the tumor microenvironment
Research output: Unpublished contribution to conference › Poster
-
Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
Research output: Contribution to journal › Article › peer-review
-
Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model
Research output: Contribution to journal › Article › peer-review
-
Projects